The mSin3 corepressor complex has been linked to diverse cancer signaling pathways through its capacity to regulate target gene expression via chromatin modification. mSds3, a cell essential gene, is a key component of the mSin3 complex serving to maintain its inherent histone deacetylase activity. mSds3 also serves an essential role in the establishment of pericentric heterochromatin, and genetic ablation of mSds3 results in chromosome missegregation. In contrast, mSin3A nullizygous cells show normal chromosome dynamics and cytogenetic profiles. The integral role of mSds3 in controlling chromosome segregation and mSin3-regulated transcriptional networks prompted efforts to determine the neoplastic impact of loss of one copy of mSds3 or mSin3A. In particular, we assessed whether loss of one copy of mSds3, alone or in combination with p53 mutation, results in aneuploidy and promotes a cancer-prone condition in the mouse. We observe that, in a p53 null background, loss of one mSds3 allele results in accelerated tumor onset and increased tumor burden. Notably, these mSds3 þ /À p53 À/À tumors exhibit a more complex cytogenetic profile characterized by marked aneuploidy and centromeric associations. The presence of even one copy of p53 is sufficient to suppress the accelerated tumorigenesis in mSds3 þ /À mice, consistent with a key role for p53 in monitoring mitotic fidelity. These observations with Sds3 mutant mice contrast with mSin3A þ /À p53 À/À mice, which do not show an accelerated or increased tumor incidence relative to mSin3A þ / þ p53
Introduction
The recent characterization of mSds3 as a key component of the mSin3 corepressor complex (Alland et al., 2002) has revealed its critical role in the maintenance of mSin3-associated histone deacetylase (HDAC) enzymatic activity. Many of the mSds3 functions are preserved in its yeast ortholog, emphasizing the significance of Sds3 in eucaryotic cell biology (Dorland et al., 2000; Lechner et al., 2000) . Genetic analysis in the mouse has also highlighted an essential role for mSds3 in initiation of the cascade of chromatin modifications, essential for the establishment of a pericentric heterochromatin state and ultimately a functional centromere (David et al., 2003) . Specifically, mSds3 deficiency was shown to result in loss of pericentric-specific histone modification and HP1 recruitment, indicating a seminal role for mSds3-HDAC in the deacetylation of newly incorporated histones in pericentric loci. As centromeres play pivotal roles in faithful distribution of the genetic information during cell division, ensuring perpetuation of a viable yet non-transformed state (Rajagopalan and Lengauer, 2004) , the loss of mSds3 function was associated with rampant aneuploidy and cell death (David et al., 2003) . Of relevance to this study, loss of mSin3A, another essential component of the mSin3 complex, did not result in aneuploidy, indicating a specific role for mSds3 in maintaining accurate chromosomal segregation (Dannenberg et al., 2005) . Many aspects of mSds3 biology touch on processes central to the development or suppression of cancer, including its roles in the proper segregation of chromosomes and the maintenance of mSin3-associated HDAC enzymatic activity. Therefore, it is assumed that key chromatin modulator complexes harboring mSds3 have the ability to modulate many cancer-relevant pathways. Although mSds3 would not be designated as a classical recessive oncogene as homozygous loss results in complete loss of cell viability (David et al., 2003) , there is mounting evidence that haploinsufficiency of certain regulatory genes can promote or suppress carcinogenesis in complex context-dependent ways (Santarosa and Ashworth, 2004) . In this study, we have conducted an in vivo genetic study to explore the impact of mSds3 haploinsufficiency on the promotion or suppression of cancer, with a particular emphasis on understanding these biological consequences in relation to chromosomal instability and p53-dependent checkpoint control.
Results and discussion
We have previously demonstrated that mSds3 deficiency results in early embryonic lethality and a cell lethal condition associated with marked aneuploidy, growth arrest and apoptosis (David et al., 2003) . That mSds3 plays an essential role in processes as fundamental as chromosomal segregation or cellular survival raised the possibility that more subtle alterations in mSds3 dosage impact on long-term organ function or cancer incidence as a function of advancing age. Thus, we monitored the physiological impact of reduced mSds3 gene dosage in an aging cohort of mSds3 heterozygous mice. mSds3 heterozygous mice are born in the expected ratio from mSds3 þ /À intercrosses and showed grossly normal organ surveys through 18 months of age (n ¼ 22 mice; Supplementary Figure S1 ). Furthermore, a limited histological survey of aged mSds3 þ / þ and mSds3 þ /À mice (ages 65-75 weeks) revealed no differences in the degree of age-associated tissue changes. Correspondingly, aged mSds3 þ / þ and mSds3 þ /À mice (ages 54-70 weeks) showed normal age-associated physiology with respect to glucose tolerance tests (n
) (data not shown). These findings suggest that mSds3 haploinsufficiency neither affects embryonic or postnatal development nor promotes a premature aging condition.
Serial analysis of mSds3 heterozygous mice (n ¼ 22) displayed normal cancer incidence through 18 months of age (data not shown). The absence of a cancer phenotype in mSds3 heterozygotes could simply convey the lack of impact of mSds3 heterozygosity on the tumorigenic process such as chromosome stability. Alternatively, it could reflect the inability of cells with chromosomal aberrations resulting from reduced mSds3 gene dosage to overcome a mitotic checkpoint, and thereby proliferate and become fully tumorigenic. To address this possibility, the tumorigenic consequences of mSds3 heterozygosity were examined in combination with germline p53 mutation. It is worth emphasizing that the use of p53 nullizygous mice was thought to be particularly instructive in dissecting the cancer-relevant activities of mSds3, as this model circumvents the p53-dependent elimination of those cells with aberrant chromosome dynamics during cell division and aneuploidy (Artandi and DePinho, 2000; Bassing et al., 2003; Fujiwara et al., 2005) .
As described previously (Jacks et al., 1994) , p53
À/À mice are highly cancer-prone, exhibiting 100% penetrance of lymphomas and/or angiosarcomas with a short mean tumor latency. Relative to mSds3
þ /À p53 À/À mice showed a more robust cancer phenotype characterized by an accelerated tumor onset ( Figure 1a ; mean latency of 12.3 versus 13.9 weeks, Po0.01) and increased tumor multiplicity per mouse (Figure 1b ; 2.45 versus 1.2 macroscopic tumors, Po0.001). The tumor spectrum was similar for the mSds3
cohorts (data not shown). The wild-type mSds3 allele was retained in all þ /À p53 À/À tumors examined (n ¼ 8; data not shown), consistent with the absolute requirement of mSds3 for the survival of primary, immortalized and transformed cells (David et al., 2003; G David and RA DePinho, unpublished data) . Consistent with what we have observed in p53 wild-type animals, comparison of large cohorts of aging mSds3
þ /À mice failed to reveal any differences in cancer phenotype as reflected by indistinguishable tumor incidence, latency, multiplicity and spectrum ( Figure 1c ; data not shown). Thus, in a p53 null setting, reduced mSds3 dosage leads to increased tumor incidence, which can be reverted by the presence of one or two functional copies of p53. The ability of even one intact copy of p53 to suppress the cancer phenotype of mSds3 þ /À mice was somewhat unexpected given that p53 haploinsufficiency is associated with partial compromise of p53 checkpoints and increased cancer incidence. In light of our findings of no increased cancer in mSds3
, coupled with the known mSin3/HDAC-directed deacetylation and activation of p53 (Kuzmichev et al., 2002; Dannenberg et al., 2005) , we speculate that Sds3 haploinsufficiency reduces overall mSin3/HDAC activity and enhances the specific activity of p53 in p53 þ /À mice. In light of mSds3's role in pericentric heterochromatin formation and chromosomal segregation (David et al., 2003) , we next investigated the level of ploidy in primary cultures derived from mSds3
À/À lymphomas or sarcomas (n ¼ 6 for each genotype). Early-passage mSds3 þ / þ p53 À/À tumor cells were often euploid whereas mSds3
À/À tumor cells were typically aneuploid with chromosome counts ranging from 30 to more than 100 (Figure 2a) . The mSds3
À/À tumor metaphases possessed multiradial chromosomes (Figure 2b ) and, in some instances, more than three chromosomes were associated through their centromeric regions -this cytogenetic feature was not observed in mSds3 þ / þ p53 À/À cells. These complex multi-chromosomal structures have been observed in mSds3 conditional knockout mouse embryonic fibroblast (MEF) cultures at a time when mSds3 levels decline following conditional deletion of both mSds3 alleles (David et al., 2003) . Together, these cytogenetic observations support the view that, in the absence of p53-dependent mitotic checkpoint, mSds3 haploinsufficiency hastens tumorigenesis by promoting aneuploidy through aberrant centromeric associations, a feature consistent with the reported functions of mSds3 in maintaining chromosomal integrity.
The mSin3/HDAC corepressor complex regulates numerous transcriptional networks relevant to cellular growth and survival and to the transformation process. Similar to Sds3 nullizygosity, the complete loss of mSin3A function is associated with a cell lethal condition and early embryonic lethality (Cowley et al., 2005; Dannenberg et al., 2005) . However, despite their close physical and functional interactions, one clear distinction between mSds3 and mSin3A is the dispensability of mSin3A in the maintenance of accurate chromosomal segregation during cell division (David et al., 2003; Cowley et al., 2005; Dannenberg et al., 2005) . This distinction provided an opportunity to dissect further whether the cancer phenotype of mSds3 heterozygosity relates its role in chromosome segregation, in the maintenance of mSin3/HDAC complex activity, or both. To this end, we monitored the cancer phenotype of mSin3A þ /À and þ /À mice in a p53 null background. In contrast to the mSds3 studies above, mSin3A
colonies showed similar cancer phenotypes. Specifically, these cohorts exhibited indistinguishable tumor incidence (Figure 3a) , tumor multiplicity ( Figure 3b ) and tumor spectrum (data not shown). Together, these studies support the view that the enhanced cancer phenotype of mSds3
À/À mice relates more to disturbances in chromosome segregation rather than possible alterations in the activity of the mSin3/HDAC complex in the regulation of cancer-relevant transcriptional networks.
The contrasting tumor phenotypes in the mSds3
þ /À and mSds3
À/À models ( Figure  1a and c) prompted speculation that, although reduced mSds3 levels engenders increased chromosomal instability in both p53
þ /À and p53 À/À mice, the presence of a functional p53 allele might enable the activation of a mitotic checkpoint resulting in the elimination of aneuploid cells. Along these lines, it is also worth noting þ /À p53 À/À tumor-derived cells.
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that previous studies have documented retention of the wild-type p53 allele in a proportion of tumors arising in p53 þ /À mice (Venkatachalam et al., 1998) . In this study, immunohistochemical analysis revealed detectable p53 protein in four of six mSds3 þ / þ p53 þ /À tumors and in five of six mSds3 Figure S2) . Therefore, the presence of p53 protein and its potential activation upon chromosomal instability, driven by decrease of mSds3 gene dosage, could provide for a more robust p53-dependent mitotic checkpoint.
In support of this notion, 3T3 growth assays with primary MEFs revealed retarded growth curves for the mSds3
þ /À controls over the first 10 passages (Figure 4a ; P ¼ 0.0057). Importantly, in the setting of p53 nullizygosity, the mSds3 þ /À cultures exhibited comparable growth rates relative to mSds3 þ / þ controls (Figure 4b ), pointing to a cell autonomous role that p53 plays in the impaired proliferation profile of mSds3 haploinsufficient cells. In light of mSds3's role in maintaining chromosomal integrity, we were specifically interested in assessing the presence of an enhanced mitotic checkpoint in mSds3 heterozygous cultures with functional p53. Consistent with the presence of a mitotic checkpoint, there was (i) lack of overt aneuploidy in these mSds3 þ /À primary cell cultures ( Figure 4c ) and (ii) increase in the average number of chromosomal associations in mSds3 þ /À MEFs compared to mSds3 þ / þ MEFs ( Figure  4d and e). It is plausible that upon mSds3 haploinsufficiency, some chromosomes become associated through their centromeric regions, promoting chromosomal missegregation in mitosis. Daughter cells with aberrant chromosome counts are then eliminated through a p53-dependent checkpoint. Collectively, these data strongly suggest that reduced mSds3 gene dosage promotes chromosomal missegregation and aneuploidy, a condition that is rapidly resolved by an intact p53-dependent checkpoint mechanism monitoring chromosome status during mitosis.
Our hypothesis that mSds3 haploinsufficiency promotes p53 activities through the activation of a mitotic checkpoint stems from the contrasting phenotypes observed in mSds3 þ /À cells and tumors with or without p53. Previous studies have reported that the absence of p53 provides a permissive context for the development of tumors resulting from chromosomal instability. For example, this relationship is well substantiated for genes of the Non-Homologous End Joining (NHEJ) pathway wherein loss of any one of a number of NHEJ genes can cooperate with p53 mutant mice to render mice highly cancer to the development of B lymphomas, often possessing complex chromosomal translocations consistent with impaired DNA double-strand break repair potential (Bassing et al., 2003; Maser and DePinho, 2003) . Similarly, p53 deficiency allows the conversion of telomere-based crisis into procarcinogenic process in mice (Chin et al., 1999) . Consistent with a contextspecific role for p53-related genome instability, previous studies have established that the genetic deletion of p53 alone in human cells exerts a relatively modest effect on genome stability (Bunz et al., 2002) .
Interestingly, we have shown that mSds3 haploinsufficiency results in aneuploidy in the absence of p53, thus correlating with increased tumor susceptibility. By contrast, mSin3A heterozygosity does not promote tumorigenesis. This is consistent with the absence of aneuploidy detected upon mSin3A acute depletion (Dannenberg et al., 2005) . The molecular mechanism by which mSds3 prevents aneuploidy remains an area of active investigation. We have shown that a small domain of the mSds3 protein that mediates the interaction with mSin3 proteins is required to prevent pericentric heterochromatin defects (David et al., 2003) . Therefore, it is formally possible that mSin3 proteins could participate in the establishment of pericentric heterochromatin which required to maintain a euploid genome. Along these lines, it is notable that mSin3A can bind centromeric regions in human cells (Xin et al., 2004) , implicating mSin3A in the pericentromeric heterochromatinization process. Thus, the lack of aneuploidy and accelerated tumorigenesis could relate to potential redundancy with the highly related mSin3B homologue which also interacts with mSds3 (Alland et al., 2002) . Alternatively, the actions of mSds3 on pericentric loci may not be dependent upon mSin3A or B function and, accordingly, recent studies have shown that a large fraction of the cellular mSds3 elutes independently of mSin3A, suggesting that mSds3 might associate with mSin3A-independent complexes (Fleischer et al., 2003) .
Although mSds3 haploinsufficiency results in accelerated tumorigenesis and overt aneuploidy in a p53-deficient background, the presence of p53 was sufficient Alteration of the mammalian Sin3 complex promotes tumorigenesis G David et al to reverse both phenotypes. This observation is consistent with the well-established ability of p53 to prevent aneuploidy-associated tumorigenesis. Along similar lines, analogous data have emerged in the study of Bub3. Specifically, despite a direct involvement of Bub3 in the mitotic checkpoint, Bub3 haploinsufficiency failed to promote tumorigenesis in a p53 heterozygous background (Kalitsis et al., 2005) . Our studies would predict that an increase in cancer incidence would emerge in Bub3 heterozygotes in a p53 null background. Similarly, the presence of p53 prevents proliferation and transformation of tetraploid murine cells (Fujiwara et al., 2005) . These observations are in agreement with our conclusion, in that p53 prevents cellular growth and tumor formation in the context of aneuploidy.
Additionally, p53 acetylation status is likely to play a role in preventing tumorigenesis in an mSds3 heterozygote background. Indeed, p53 acetylation correlates with its activation and its tumor suppressor potential (Gu and Roeder, 1997; Luo et al., 2000) . As the mSin3 complex has been involved in the regulation of p53 acetylation, it is tempting to speculate that mSds3 gene dosage may influence p53 status. In this regard, our understanding of the modulation of p53 post-translational modifications, as it relates to its biological activities, remains largely circumstantial. Genotoxic stress induces a phosphorylation-acetylation cascade, which results in p53 activation (Sakaguchi et al., 1998) . However, whether p53 acetylation, in the absence of prior phosphorylation, is sufficient to induce p53 biological activities has not been definitively ascertained. Pharmacological inhibition of HDAC using trichostatin A results in p53 hyperacetylation, which correlates with its stabilization (Ito et al., 2001 ). However, it is possible that such stabilization results from chromosomal missegregation induced by HDAC inhibition, as we have previously reported in mSds3-inactivated cells (David et al., 2003) . Conversely, forced deacetylation of p53, mediated the promyelocytic leukemia-retinoic acid receptor a or promyelocytic leukemia zinc-fingerretinoic acid receptor a chimeric oncoproteins, directly inactivates p53 biological functions (Insinga et al., 2004) . Such observations are consistent with a requirement for p53 acetylation to exert its tumor-preventing functions, and suggest that p53 acetylation/deacetylation is a dynamic process that occurs continuously As revealed by our analysis of the transcriptome of cells acutely deleted for mSin3A, the mSin3 complex participates in numerous transcriptional pathways that regulate cell proliferation and differentiation (Dannenberg et al., 2005) . The potential of 'transcriptional therapy' in cancer, by which the normal, non-malignant transcriptional program is restored, is under study with the development and deployment of Histone Deacetylase inhibitors (HDACi) in clinical anticancer trials (Marks et al., 2004) . Our results suggest that a targeted and rational inhibition of specific components of the mSin3 complex might circumvent the common concern of chromosomal instability that would result from global HDAC inhibition. It is our view that an in-depth knowledge of the molecular targets of the class I HDACs and associated complexes (such as mSin3/ mSds3) will result in the development of HDACi that target optimal HDAC complex components. Our study has illuminated at least one aspect of this complex network by revealing that diminished mSds3, and by inference mSin3/HDAC-associated activities, can promote chromosomal instability and tumorigenesis only in the absence of a functional p53 mitotic checkpoint. To our knowledge, this is the first demonstration that altering the activity of a specific HDAC-containing complex in vivo can promote tumorigenesis in the absence of a functional mitotic checkpoint. p53 is inactivated, directly or indirectly, in most but not all human tumors. Therefore, it will be critical to correlate the efficiency of HDACi as anticancer drugs with the presence of p53 in the treated tumors. Our results suggest that in specific settings, including the absence of a functional p53 checkpoint, inhibition of HDAC activity could have deleterious long-term effects by promoting tumor initiation/progression via chromosomal instability.
Materials and methods

Generation and monitoring of mice
The mSds3 and mSin3A null alleles have been described elsewhere (David et al., 2003; Dannenberg et al., 2005) . mSds3 or mSin3A mice were crossed with p53 heterozygotes mice (Jacks et al., 1994) and the colony was maintained in a FVB/ C57Bl6 mixed background. Mice were followed weekly for tumor onset and killed at signs of ill health. Tumor cultures were established in Rosewell's Park Memorial Institute medium þ 10% fetal bovine serum þ 20% Methoccult (Stem Cell Technology, Vancouver).
Cellular analysis
Early-passage tumor culture and mouse primary fibroblasts (MEFs) were processed for metaphases spreads, as described in David et al. (2003) . Briefly, cells were treated with colchemid for 2-4 h, incubated in 0.075 M KCl for 20 min, and fixed in methanol/acetic acid. Metaphases were then dropped onto slides and the chromosomes were counted. For cell growth assays, standard 3T3 protocols were conducted on earlypassage (Passageo4) MEFs.
